Wegovy Pill / Oral Semaglutide 25 mg (Weight Management)

The oral Wegovy pill (oral semaglutide 25 mg) is the first FDA-approved oral GLP-1 specifically for weight management, eliminating the need for self-injection while matching injectable Wegovy's efficacy. Approved on December 22, 2025, and launched in January 2026, the OASIS 4 Phase 3 trial showed adherent participants lost an average of 16.6% body weight, with one-third achieving at least 20% weight loss compared to under 3% for placebo. Its cardiovascular risk-reduction indication adds clinical depth. However, the strict fasting requirement—no food for 6 hours, only 4 oz of water, and a 30-minute post-ingestion wait—creates adherence challenges. This dosing protocol is stricter than Foundayo (orforglipron), which can be taken at any time without food restrictions. At a list price of $499 per month with savings programs, it is a potent but logistically demanding option.